Molecular diagnostics and targeted treatment of lung cancer - A solution to select personalized treatments — Oncompass Medicine
A tüdőrák molekuláris diagnosztikája és célzott kezelése

The vast majority of lung cancers carry mutations that are targets for targeted therapies. 

In the treatment of tumours, in addition to the classical oncological approach, precision oncology is increasingly gaining ground, resulting in a therapy that is selected based on the molecular properties of the tumour.

While in the classical oncological approach the treatment decision was based on the histological type and extent of the tumour, the knowledge of the molecular information of the tumours is essential for the choice of a personalized treatment. Molecular diagnostics and Oncompass Medicine’s multi-award-winning medical software help here.

For targeted treatment of lung cancer, a molecular diagnostic is needed before starting therapy.

Register for a personal or online consultation!

Molecular diagnostics

All cancers have a genetic origin, and for many of the genetic mutations that cause cancer, personalized oncological treatment can already be given. Molecular diagnostics reveals the cause of the cancer, and based on the identified gene mutations, we use our proprietary, specialized medical software to identify the target of the tumour, or molecular target, and the personalized drugs that can be associated with that target.

Learn more about molecular diagnostics!
1606211112252

Depending on the size and appearance of the lung cancer cells on microscopic examination, two histological classifications are distinguished: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).

Other non-epithelial malignancies, such as sarcomas, also occur in the lungs, and it is very common for secondary, metastatic tumours to occur when the primary tumour is in another organ, and these are treated differently.

The first-line treatment for advanced or metastatic lung cancer is drug therapy: chemotherapy or targeted and/or immunotherapy based on molecular information.

For lung cancers with EGFR, ALK/ROS1 mutations, targeted treatment is with low molecular weight tyrosine kinase inhibitor (TKI) oral drugs.

Several genes are known to be responsible for tumour development in lung cancer, such as HER, BRAF, KRAS, MET, KIT, RET, FGFR1, NRG1, which are additional therapeutic targets.

Targeted treatment can only be safely based on a detailed genetic profile of the tumour, which is the only way to understand the behaviour of the tumour at the molecular level. In most cases, 600 genes are tested, with additional specific tests.

Of the 25,000 coding human genes, 600 are associated with tumor development. On average 4-5 different genes mutations per tumor are responsible for uncontrolled cell division. Therefore a detailed genetic profiling of a given tumor is necessary for making the right therapeutic decision. The more mutations are present in a tumor, the harder it is to select for molecular targets.

Digital therapy planning

Digital therapy planning refers to the personalized treatment and immunotherapy planning using digital drug assignment.

Our multiple times award-winning medical software, used for digital therapy planning, is unique in being able to rate and prioritize targeted treatment options within 20 milliseconds in 405 tumor types, based on 52 000 mutations, 26 838 rules and 1417 compounds using up to date scientific evidence.

Oncompass Medicine’s medical software helps doctors select the most effective, personalized, targeted treatment options for cancer patients in 20 milliseconds.

Find out more about digital therapy planning!
Find out more about targeted treatment options for lung cancer

Precision Oncology Program

The framework of the personalized program is provided by a new medical procedure developed by Oncompass. The procedure includes all the services needed to set up a personalized treatment plan and puts them in an optimal order. The special procedure can help you and your doctor to identify and to apply personalized options.

Learn about the personalized program

Make an appointment for consultation

Asco Breakthrough

ASCO Breakthrough Innovations in Oncology

2019 Read more
More

About us

Our story

2003— —2024

Oncompass Medicine is a Hungarian medical enterprise dealing with the development of decision support and diagnostic medical devices that help the personalized treatment of cancer patients. 

More information